Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Nathifa Moyo, Annette B. Vogel, Søren Buus, et al.
Molecular Therapy — Methods & Clinical Development (2018) Vol. 12, pp. 32-46
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 984
Advances in mRNA Vaccines for Infectious Diseases
Cuiling Zhang, Giulietta Maruggi, Hu Shan, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 607
The Limitless Future of RNA Therapeutics
Tulsi Ram Damase, Roman Sukhovershin, Christian Boada, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 440
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 409
Self-amplifying RNA vaccines for infectious diseases
Kristie Bloom, Fiona T. van den Berg, Patrick Arbuthnot
Gene Therapy (2020) Vol. 28, Iss. 3-4, pp. 117-129
Open Access | Times Cited: 343
An Update on Self-Amplifying mRNA Vaccine Development
Anna K. Blakney, Shell Ip, Andrew J. Geall
Vaccines (2021) Vol. 9, Iss. 2, pp. 97-97
Open Access | Times Cited: 195
Formulation and Delivery Technologies for mRNA Vaccines
Chunxi Zeng, Chengxiang Zhang, Patrick Walker, et al.
Current topics in microbiology and immunology (2020), pp. 71-110
Open Access | Times Cited: 179
A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
Peng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2234-2245
Open Access | Times Cited: 126
Nanomedicine-Based Approaches for mRNA Delivery
Satoshi Uchida, Federico Perche, Chantal Pichon, et al.
Molecular Pharmaceutics (2020) Vol. 17, Iss. 10, pp. 3654-3684
Open Access | Times Cited: 112
Messenger RNA-Based Vaccines Against Infectious Diseases
Mohamad‐Gabriel Alameh, Drew Weissman, Norbert Pardi
Current topics in microbiology and immunology (2020), pp. 111-145
Closed Access | Times Cited: 85
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
Kailash C. Petkar, Suyash M. Patil, Sandip S. Chavhan, et al.
Pharmaceutics (2021) Vol. 13, Iss. 4, pp. 455-455
Open Access | Times Cited: 81
Current approaches to HIV vaccine development: a narrative review
Jiae Kim, Sandhya Vasan, Jérôme H. Kim, et al.
Journal of the International AIDS Society (2021) Vol. 24, Iss. S7
Open Access | Times Cited: 74
HIV mRNA Vaccines—Progress and Future Paths
Zekun Mu, Barton F. Haynes, Derek W. Cain
Vaccines (2021) Vol. 9, Iss. 2, pp. 134-134
Open Access | Times Cited: 72
The Delivery of mRNA Vaccines for Therapeutics
Nitika Nitika, Wei Jiao, Ai‐Min Hui
Life (2022) Vol. 12, Iss. 8, pp. 1254-1254
Open Access | Times Cited: 54
Self-Amplifying RNA Approach for Protein Replacement Therapy
Dimitri Papukashvili, Nino Rcheulishvili, Cong Liu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12884-12884
Open Access | Times Cited: 39
Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
Christin Schmidt, Barbara S. Schnierle
Pathogens (2023) Vol. 12, Iss. 1, pp. 138-138
Open Access | Times Cited: 39
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Laura Matarazzo, Paulo Bettencourt
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 39
Advanced technologies for the development of infectious disease vaccines
Akash Gupta, Arnab Rudra, Kaelan Reed, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 914-938
Closed Access | Times Cited: 11
Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles
Mariane B. Melo, Ely Porter, Yuan Zhang, et al.
Molecular Therapy (2019) Vol. 27, Iss. 12, pp. 2080-2090
Open Access | Times Cited: 75
Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen
Tamara G. Dacoba, Robert W. Omange, Hongzhao Li, et al.
ACS Nano (2019) Vol. 13, Iss. 5, pp. 4947-4959
Open Access | Times Cited: 73
A new generation of vaccines based on alphavirus self-amplifying RNA
María Cristina Ballesteros-Briones, Noelia Silva-Pilipich, Guillermo Herrador, et al.
Current Opinion in Virology (2020) Vol. 44, pp. 145-153
Open Access | Times Cited: 70
HIV vaccinology: 2021 update
Jeong Hyun Lee, Shane Crotty
Seminars in Immunology (2021) Vol. 51, pp. 101470-101470
Open Access | Times Cited: 46
Prophylactic HIV-1 vaccine trials: past, present, and future
Joseph P. Nkolola, Dan H. Barouch
The Lancet HIV (2023) Vol. 11, Iss. 2, pp. e117-e124
Open Access | Times Cited: 21
Advanced nanoscale delivery systems for mRNA-based vaccines
Maha W. Mobasher, Rais A. Ansari, Ana M. Castejón, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2024) Vol. 1868, Iss. 3, pp. 130558-130558
Closed Access | Times Cited: 8
The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines
Jeffrey E. Harris
(2021)
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top